businesspress24.com - Innoviva to Report Fourth Quarter and Full Year 2015 Financial Results on February 3, 2016
 

Innoviva to Report Fourth Quarter and Full Year 2015 Financial Results on February 3, 2016

ID: 1411584

(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/27/16 -- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and full year ended December 31, 2015 after market close on Wednesday, February 3, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EST that day to discuss the financial results and provide a corporate update.

To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 36373209.

Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva''s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva''s website at .

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)



Eric d''Esparbes
Senior Vice President and Chief Financial Officer




650-238-9640

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  INTEGA Skin Looks GUD to Knight
MSI Methylation Sciences Inc. (MSI) Announces Results From the Horizon Phase 2 Trial for its Novel Treatment, MSI-195, for Major Depressive Disorder (MDD)
Bereitgestellt von Benutzer: Marketwired
Datum: 27.01.2016 - 15:05 Uhr
Sprache: Deutsch
News-ID 1411584
Anzahl Zeichen: 3318

contact information:
Contact person:
Town:

SOUTH SAN FRANCISCO, CA


Phone:

Kategorie:

Drugs


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 237 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Innoviva to Report Fourth Quarter and Full Year 2015 Financial Results on February 3, 2016
"
steht unter der journalistisch-redaktionellen Verantwortung von

Innoviva, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Innoviva, Inc.



 

Who is online

All members: 10 563
Register today: 2
Register yesterday: 2
Members online: 0
Guests online: 111


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.